Watson Pharmaceuticals / Actavis Inc.

Last Updated:
In the Matter of Watson Pharmaceuticals Inc., Actavis Inc., Actavis Pharma Holding 4 ehf., and Actavis S..r.l.
FTC Matter/File Number:


Docket Number:


Enforcement Type:

Part 2 Consents

Case Summary

On 10/15/2012, The FTC required Watson Pharmaceuticals, Inc. and Actavis Inc. to sell the rights and assets to 18 drugs to Sandoz International GmbH and Par Pharmaceuticals, Inc, and relinquish the manufacturing and marketing rights to three others, to settle charges that Watson’s proposed $5.9 billion acquisition of Actavis would otherwise be anticompetitive. The settlement protects competition in the markets for 21 current and future generic drugs, used to treat a wide range of conditions ranging from hypertension and diabetes to anxiety and attention deficit hyperactivity disorder (ADHD). It is part of the FTC’s ongoing effort to promote competition in the health care sector, which benefits U.S. consumers by keeping prices low and quality and choice of products and services high. On 12/14/2012, the FTC approved a final order settling charges that Watson Pharmaceuticals, Inc's proposed acquisition of Actavis Inc. would have been anticompetitive in the markets for 21 current and future generic drugs.

There is a related federal proceeding and two related administrative proceedings: